Saratov JOURNAL of Medical and Scientific Research

Polybiomarker approach in myocardial dysfunction assessment in senile patients

Year: 2015, volume 11 Issue: №1 Pages: 031-036
Heading: Gerontology and geriatrics Article type: Original article
Authors: Malinova L.I., Podbolotov R.A., Povarova T.V., Avdienko I.V.
Organization: Regional Hospital for War Veterans, Saratov, Saratov State Medical University

Purpose: to evaluate interaction of obesity, inflammation and myocardial dysfunction in senile myocardial infarction survivors. Material and Methods. Patients aged 70 and older were involved in the study (n=108) and divided into 2 groups according to the history of myocardial infarction (Ml) — 5 years before involvement: senile Ml survivors (n=26) vs senile patients without history of Ml (n=82). Measurements of serum levels of adipokines (leptin, adiponectin), myocardial dysfunction markers (BNP, NT proBNP, proANP, galectin 3) and inflammatory cytokines (TNF, interleukin 6) were performed. Results. Both groups were comparable by age and major clinical characteristics. Ejection fraction was preserved in both groups under the study (67 (64; 70) %vs67 (64; 68) %, p=0,655). Frequency of diastolic dysfunction was comparable in both groups. However it was more severe in Ml survivors. BNP and NT proBNP levels were significantly lower in patients without the history of Ml (p=0,021; 0,004, respectively). On the contrary serum levels of proANP had tendency to increase in patients with the history of Ml, but not significantly: p=0,821. Adiponectin and galectin-3 were significantly higher in patients with the history of Ml (p=0,019and p=0,011). Conclusion. Pathogenetic peculiarities of chronic heart failure with preserved ejection fraction in senile patients with and without myocardial infarction history were revealed. More expedient biomarker panel appropriate for senile patients with probable heart failure should include NT-proBNP, galectin-3 and adiponectin.

1. Kirchhof P, Sipido KR, Cowie MR, et al. The continuum of personalized cardiovascular medicine: a position paper of the European Society of Cardiology. Eur Heart J 2014; 35: 3250-7
2. Beamish RE. Heart failure: the ironic failure of success. Can JCardioM994;10:603
3. Fomin IV, Belenkov YuN, Mareev VYu, Ageev FT, et al. Prevalence of chronic heart failure in the european part of the russian federation: data from EPOCH-CHF. Heart failure Journal 2006; 7: 4-7
4. Emdin М, Vittorini S, Passino С, Clerico A. Old and new biomarkers of heart failure. European Journal of Heart Failure 2009; 11:331-335
5. Mareev VYu, Ageev FT, Arutyunov GP, et al. National HFA, RCS and RSMST guidelines for the diagnosis and treatment of chronic heart failure. Heart failure Journal 2013; 14: 379-472
6. McMurray JJ, Adamopoulos S, Anker SD, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2012; 14: 803-69
7. McGann PE. Comorbidity in heart failure in the elderly. Clin Geriatr Med 2000; 16: 631-48
8. Dzau VJ, Antman EM, Black HR, et al. The cardiovascular disease continuum validated: clinical evidence of improved patient outcomes: part II: Clinical trial evidence (acute coronary syndromes through renal disease) and future directions. Circulation 2006; 114:2871-91
9. Deurenberg P, van der Kooy K, Leenen R, et al. Sex and age specific prediction formulas for estimating body composition from bioelectrical impedance: a cross-validation study. Int J Obes 1991; 15: 17-25
10. Deurenberg P, Weststrate JA, Seidell JC. Body mass index as a measure of body fatness: age- and sex-specific prediction formulas. Br J Nutr 1991; 65: 105-148 11. Rebrova OY Statistical analysis of medical data: Statistics and analytics software package STATIS-TICA application. Moscow: Media Sphera, 2006
12. Yancy CW, Jessup М, Bozkurt В, et al. 2013 ACCF/ AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation /American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013; 62: e147-239
13. MacGowan GA, Mann DL, Kormos RL, et al. Circulating interleukin-6 in severe heart failure. Am J Cardiol 1997; 79: 1128-31
14. Muller-Ehmsen J, Schwinger RH. TNF and congestive heart failure: therapeutic possibilities. Expert Opin Ther Targets 2004; 8: 203-98 15. Anker SD, Coats AJ. How to RECOVER from RENAISSANCE? The significance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACH. Int J Cardiol 2002; 86: 123-30
16. Bruunsgaard H. Effects of tumor necrosis factor-alpha and interleukin-6 in elderly populations. Eur Cytokine Netw 2002; 13:389-91
17. Bruunsgaard H, Pedersen M, Pedersen BK. Aging and proinflammatory cytokines. Curr Opin Hematol 2001; 8: 131 -6
18. Maisel A. B-type natriuretic peptide measurements in diagnosing congestive heart failure in the dyspneic emergency department patient. Rev Cardiovasc Med 2002; 3 Suppl 4: S10-7
19. Mehra MR, Uber PA, Park MH, et al. Obesity and suppressed B-type natriuretic peptide levels in heart failure. J Am Coll Cardiol 2004; 43: 1590-5
20. Grandin EW, Jarolim P, Murphy SA, et al. Galectin-3 and the development of heart failure after acute coronary syndrome: pilot experience from PROVE IT-TIMI 22. Clin Chem 2012;58:267-73
21. Weber M, Sporrer D, Weigert J, et al. Adiponectin downregulates galectin-3 whose cellular form is elevated whereas its soluble form is reduced in type 2 diabetic monocytes. FEBS Lett 2009; 583: 3718-24
22. Kiwaki K, Novak CM, Hsu DK, et al. Galectin-3 stimulates preadipocyte proliferation and is up-regulated in growing adipose tissue. Obesity (Silver Spring) 2007; 15: 32-9
23. Lam KS, Xu A. Adiponectin: protection of the endothe-lium. Curr Diab Rep 2005;5:254-9
24. Kadowaki T, Yamauchi T, Kubota N, et al. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest 2006; 116: 1784-92
25. Tilg H, Wolf AM. Adiponectin: a key fat-derived molecule regulating inflammation. Expert Opin Ther Targets 2005; 9: 245-51
26. Ohashi K, Kihara S, Ouchi N, et al. Adiponectin replenishment ameliorates obesity-related hypertension. Hypertension 2006; 47: 1108-16
27. Hashimoto N, Kanda J, Nakamura T, et al. Association of hypoadiponectinemia in men with early onset of coronary heart disease and multiple coronary artery stenoses. Metabolism 2006; 55: 1653-7
28. Patel DA, Srinivasan SR, Xu JH, et al. Adiponectin and its correlates of cardiovascular risk in young adults: the Bogalusa Heart Study. Metabolism 2006; 55: 1551-7
29. Pischon T, Rimm EB. Adiponectin: a promising marker for cardiovascular disease. Clin Chem 2006; 52:

2015_01_031-036.pdf893.87 KB

No votes yet